Abstract
Anti-diabetic drugs have, in addition to their well-known glucose lowering-effect, different effects in the rest of cardiovascular factors that are associated with diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have recently been incorporated to the therapeutic arsenal of type 2 diabetes mellitus. The objective of this review is to summarize the available evidence on the effect of the GLP-1 receptor agonists on different cardiovascular risk factors, mediated by the effect of GLP-1 receptor agonists on the control of hyperglycaemia and the GLP-1 receptor agonists effect on other cardiovascular risk factors (weight control, blood pressure control, lipid profile and all other cardiovascular risk biomarkers). In addition, we present the emerging evidence with regards to the impact that GLP-1 receptor agonists therapy could have in the reduction of cardiovascular events and the currently ongoing studies addressing this issue.
Keywords:
Cardiovascular risk; Diabetes mellitus tipo 2; Glucagon-like peptide-1; Péptido tipo 1 similar al glucagón; Riesgo cardiovascular; Type 2 diabetes mellitus.
Copyright © 2012 Elsevier España, S.L. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Blood Glucose / analysis
-
Brain / drug effects
-
Brain / metabolism
-
Cardiovascular Diseases / complications
-
Cardiovascular Diseases / prevention & control*
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dyslipidemias / complications
-
Exenatide
-
Gastric Emptying / drug effects
-
Gastric Emptying / physiology
-
Glucagon-Like Peptide 1 / agonists*
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / pharmacology
-
Glucagon-Like Peptide 1 / physiology
-
Glucagon-Like Peptide 1 / therapeutic use
-
Heart / drug effects
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / biosynthesis
-
Insulin / metabolism
-
Insulin Secretion
-
Islets of Langerhans / drug effects
-
Islets of Langerhans / metabolism
-
Liraglutide
-
Liver / drug effects
-
Liver / metabolism
-
Meta-Analysis as Topic
-
Obesity / complications
-
Obesity / drug therapy
-
Peptides / pharmacology
-
Peptides / therapeutic use*
-
Risk
-
Venoms / pharmacology
-
Venoms / therapeutic use*
-
Weight Loss
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin
-
Peptides
-
Venoms
-
Liraglutide
-
Glucagon-Like Peptide 1
-
Exenatide